Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 16.

Burkard, T; Pfister, O; Rickli, H; Follath, F; Hack, D; Zaker, R; Pittl, U; Handschin, R; Pfisterer, M; Brunner-La Rocca, H P; Time-CHF Investigators (2014). Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure. QJM : An International Journal of Medicine, 107(2):131-138.

Follath, F; Yilmaz, M B; Delgado, J F; Parissis, J T; Porcher, R; Gayat, E; Burrows, N; McLean, A; Vilas-Boas, F; Mebazaa, A (2011). Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Medicine, 37(4):619-626.

Mebazaa, A; Pitsis, A A; Rudiger, A; Toller, W; Longrois, D; Ricksten, S E; Bobek, I; De Hert, S; Wieselthaler, G; Schirmer, U; von Segesser, L K; Sander, M; Poldermans, D; Ranucci, M; Karpati, P C J; Wouters, P; Seeberger, M; Schmid, E R; Weder, W; Follath, F (2010). Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical Care, 14(2):201.

Rudiger, A; Businger, R; Streit, M; Schmid, E R; Maggiorini, M; Follath, F (2009). Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Medical Weekly, 139(7-8):110-116.

Breitenstein, A; Stämpfli, S F; Camici, G G; Akhmedov, H R; Ha, H R; Follath, F; Bogdanova, A; Lüscher, T F; Tanner, F C (2008). Amiodarone inhibits arterial thrombus formation and tissue factor translation. Arteriosclerosis Thrombosis and Vascular Biology, 28(12):2231-2238.

Komajda, M; Hanon, O; Hochadel, M; Lopez-Sendon, J L; Follath, F; Ponikowski, P; Harjola, V P; Drexler, H; Dickstein, K; Tavazzi, L; Nieminen, M (2008). Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European Heart Journal, 30(4):478-486.

Rivero-Ayerza, M; Scholte op Reimer, W; Lenzen, M; Theuns, D A; Jordaens, L; Komajda, M; Follath, F; Swedberg, K; Cleland, J G (2008). New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. European Heart Journal, 29(13):1618-1624.

Stadler, K; Ha, H R; Ciminale, V; Spirli, C; Saletti, G; Schiavon, M; Bruttomesso, D; Bigler, L; Follath, F; Pettenazzo, A; Baritussio, A (2008). Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. American Journal of Respiratory Cell and Molecular Biology, 39(2):142-149.

Fischer, A H; van der Loo, B; Shär, G M; Zbinden, R; Duru, F; Brunckhorst, C; Rousson, V; Delacrétazy, E; Stuber, T; Oechslin, E N; Follath, F; Jenni, R (2008). Serological evidence for the association of Bartonella henselae infection with arrhythmogenic right ventricular cardiomyopathy. Clinical Cardiology, 31(10):469-471.

Rudiger, A; Burckhardt, O A; Harpes, P; Müller, S A; Follath, F (2006). The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. American Journal of Emergency Medicine, 24(4):451-4.

Spannheimer, A; Müller, K; Falkenstein, P; Reitberger, U; Gutzwiller, Felix; Follath, F (2002). Diuretika-Langzeitbehandlung bei Herzinsuffizienz: Gibt es Unterschiede zwischen Furosemid und Torasemid? Praxis, 91(37):1467-1475.

Dazzi, H; Kaufmann, K; Follath, F (2001). Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Annals of Oncology, 12(7):963-966.

Fattinger, K; Roos, Malgorzata; Spiess, A; Vergères, P; Braunschweig, S; Kullak-Ublick, G A; Galeazzi, R L; Follath, F; Schaffner, A; Gasser, T; Meier-Abt, P J (2000). Die "Stiftung für Arzneimittelsicherheit" SAS/CHDM: Update 2000. Schweizerische Ärztezeitung (SÄZ), 81(42):2381-2384.

Truninger, K; Attenhofer Jost, C H; Seifert, Burkhardt; Vogt, P R; Follath, F; Schaffner, A; Jenni, R (1999). Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart, 82(6):714-720.

Fattinger, K E; Roos, Malgorzata; Vergères, P; Holenstein, C; Kind, B; Stocker, D N; Masche, U; Braunschweig, S; Galeazzi, R L; Follath, F; Gasser, Theo; Meier-Abt, P J (1998). Die "Stiftung für Arzneimittelsicherheit SAS/CHDM": strukturierte Datenerfassung und erste Resultate zu unerwünschten Arzneimittelwirkungen bei hospitalisierten, internistischen Patienten. Schweizerische Ärztezeitung (SÄZ), 79(51):2615-2618.

Oechslin, E; Kiowski, W; Schneider, J; Follath, F; Turina, M; Gallino, A (1996). Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. Annals of Oncology, 7(10):1059-1063.

This list was generated on Wed Feb 20 17:03:10 2019 CET.